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Abstract
Background: The syndrome of resistance to thyroid hormone (RTH) is caused by mutations in the thyroid hormone
receptor b gene (THRB). The syndrome varies from asymptomatic to diffuse hypothyroidism, to pituitary-selective
resistance with predominance of hyperthyroid signs and symptoms. The wide spectrum of clinical presentation is not
completely attributable to specific THRB mutations. The THRB gene encodes two main isoforms, TR b1 which is
widely distributed, and TR b2, whose expression is limited to the cochlea, retina, hypothalamus, and pituitary. Recent
data demonstrated that in mice an intron enhancer region plays a critical role in the pituitary expression of the b2
isoform of the receptor. We thus hypothesized that polymorphisms in the human homologous region could
modulate the pituitary expression of the mutated gene contributing to the clinical presentation of RTH.
Methods: Screening and in vitro characterization of polymorphisms of the intron enhancer region of the THRB
gene in the index case of pituitary-selective RTH.
Results: The index case of pituitary-selective resistance is characterized by the missense R338W exon 9 mutation in
cis with two common SNPs, rs2596623T and rs2596622C, located in the intron enhancer region of the THRB gene.
Reporter gene assay experiments in GH3 pituitary-derived cells indicate that rs2596623T generates an increased
pituitary cell-specific activity of the TR b2 promoter suggesting that rs2596623T leads to pituitary over-expression of
the mutant allele.
Conclusions: The combined coding mutation and non-coding SNP therefore generate a tissue-specific dominant-
negative condition recapitulating the patient’s peculiar phenotype. This case illustrates the role of regulatory
regions in modifying the clinical presentation of genetic diseases.
Background
Mutations in the THRB gene, encoding thyroid hormone
receptor b (TRb), result in the syndrome of resistance to
thyroid hormone (RTH)[1,2]. RTH is a rare autosomal
dominant disease with two main clinical presentations.
The generalized RTH (GRTH) is characterized by
elevated levels of TH, inappropriately normal or elevated
levels of TSH [3], and a variable clinical presentation,
ranging from asymptomatic to severe hypothyroidism
[4,5]. A rarer form of RTH is characterized by selective
resistance mostly limited to the pituitary (PRTH), with a
prevalence of hyperthyroid symptoms since peripheral
tissues are relatively less resistant to TH action but are
exposed to elevated TH levels [6]. Most RTH mutations
are localized in “hot spots” in the C-terminal coding
exons of THRB, that generate dominant negative proteins
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ences among the clinical presentations, there is a lack of
strict genotype-phenotype correlation and identical
THRB gene mutations have been observed in PRTH or
GRTH patients [8].
The THRB gene expresses N-terminal variant TR b1a n d
TR b2 isoforms from specific promoters (Figure 1A). TR
b1 is relatively widely expressed whereas TR b2i s
restricted with main sites of expression in the anterior
pituitary, hypothalamus, cochlea and retina [9,10]. A con-
served 600 bp intron control region (ICR) directs expres-
sion of TR b2 in the pituitary and retina in transgenic
mice [10]. In this study we investigate SNPs in the ICR of
the human THRB gene in RTH. The screening of the ICR
in our RTH cohort demonstrated the presence of a novel
and four common SNPs. We also report that in the index
case of PRTH a common SNP in the ICR stimulates over-
activation of the TR b2 promoter in pituitary cells in vitro.
Moreover, we determined that this SNP is linked in cis
with the known R338W coding mutation. We propose
that this genetic “double hit” of coding and non-coding
changes in the same THRB allele, ultimately generates a
tissue-specific dominant negative condition underlying
this case of PRTH.
Methods
Patients and specimens
All patients provided an informed consent to the partici-
pation in the study and the collection of genetic mate-
rial. Medical records of 45 RTH patients followed at the
NIH Clinical Center since 1976, for whom DNA sam-
ples were available, were reviewed [8]. The cases were
categorized as either GRTH or PRTH; the diagnosis of
PRTH was made if at least two of the following findings
were described in the medical records: resting tachycar-
dia, resting energy expenditure >110% of predicted by
the Harris-Benedict formula [11], hyperactive behavior,
and low body mass index (<20 kg/m
2 in adults or <5
th
percentile in children).
Genomic DNA amplification and sequencing
Exons 9, 10, and a 607 bp ICR fragment of the THRB gene
of the index case of pituitary selective RTH were amplified
and screened for mutations by direct sequencing. Each
PCR was performed using Platinum
® Taq from Invitrogen
(Carlsbad, CA) using the following primers: exon 9: 5’-
GAAAACCATGGGCTCAAAGA-3’,a n d5 ’-AGCGCTAG
ACAAGCAAAAGC-3’; exon 10: 5’-TAAAGGCCTG-
GAATTGGACA-3’ and 5’-TCCCTCCCAACACAAAG
AAA-3’; ICR: 5-TGAGGTACATTGAACATGTGC-3’ and
5’-ACTGAACACCTGTTTATGGTC-3’. The sequences
were analyzed and visually inspected using Sequence Scan-
ner 1.0 (Applied Biosystems, Foster City, CA).
Figure 1 THRB gene structure, location and transcriptional
activity of ICR SNPs. A. Diagram of the THRB gene showing the
origins of the TR b1- and TR b2-specific transcripts. The gray square
represents the conserved 600 bp TR b2-specific intron control
region (ICR), homologous to the mouse sequence. The location of
the exonic R338W mutation in the index case of PRTH is marked by
a vertical line. Major TR b1-specific 5’ exons are shown, but not all
variable untranslated sequences of TR b1 transcripts are included
[24]. B, Luciferase reporter gene constructs, showing in the lower
half of the panel the location of SNPs found in the ICR (rs6798561
a, rs17194828 b, rs2596623 g, rs2596622 δ, rs77624520 ε). C,
Transcriptional activity of the reporter constructs; genomic sequence
origin, human (Hs, Homo sapiens), mouse (Mm, Mus musculus).
Compared to the human promoter alone, the human promoter plus
ICR gave a 10-fold increase in pituitary cell-specific luciferase
expression. Constructs containing the murine promoter and ICR are
included as positive controls for ICR activity. Analysis of the chimeric
reporter (human promoter + mouse ICR) indicated that the ICR
activity is conserved. No activity of the ICR was observed in kidney-
derived HEK-293T cells (see text for details). * = significant on Tukey’s
post-hoc analysis.
Alberobello et al. Journal of Translational Medicine 2011, 9:144
http://www.translational-medicine.com/content/9/1/144
Page 2 of 7Reporter gene constructs
A 589 bp human TR b2 promoter fragment homologous
to the mouse promoter [12] and a 691 bp ICR fragment
were directionally cloned into a luciferase reporter con-
struct in a pRep4 episomal vector [10]. Fragments were
amplified by PCR from a healthy, unrelated subject using
primers as follows: promoter: 5’-GGT-Nhel-TCATTAC-
TACTGGATTTTC-3’ and 5’-TGG-HindIII-GTTTCCCT
GGTTCAGTTTC-3’;I C R :5 ’-GTT-BamHI-TAATG-
GAAACATTTGAGGT-3’and 5’-GAA-SalI-AGATGAAG-
CAATTATGAAC-3’.T h i sc o n s t r u c tw a su s e da sa
template to generate mutations in the ICR using Quik-
Change™ Site-Directed Mutagenesis (Stratagene, La Jolla,
CA) (Figure 1B). A promoterless construct containing the
ICR, and a construct lacking the ICR but containing the
TR b2 promoter were generated as negative controls.
A chimeric construct contained the human promoter and
a mouse ICR (730bp ICR fragment of mouse Thrb gene
obtained by PCR) (NC_00085.5) as described [10]. All
constructs were sequenced in entirety.
Transfection and luciferase assay
Media, sera, antibiotics for cell culture, and transfection
reagents were purchased from Invitrogen (Carlsbad, CA).
GH3 or HEK-293T cells (6 × 10
3 cells/cm
2)w e r eg r o w ni n
DMEM supplemented with 10% (v/v) FBS and 2 mM glu-
tamine. Cultures were maintained at 37°C in a humidified
atmosphere containing 5% (v/v) CO2.
Transfections with 200 ng of each luciferase reporter
plasmid, 20 ng of pSV-RL Renilla internal control plas-
mid, and empty pcDNA-3 carrier DNA were performed
with Lipofectamine™. Thirty-six hours after transfection,
the cells were kept in serum-free medium overnight
before harvesting. Luciferase activity was assayed with a
dual-luciferase system and normalized to renilla activity
(Promega, Madison, WI).
Statistical Analysis
The frequency of categorical variables (clinical characteris-
tics and generalized vs. pituitary-selective RTH) was ana-
lyzed by chi-square, while continuous variables (luciferase
reporter assay data) were assessed by one-way ANOVA
with Tukey’s post-hoc analysis. An a error of 0.05 was
considered the threshold for statistical significance.
Results
Case presentation
This case was originally described by Gershengorn and
Weintraub in 1975 [6]. This female patient, currently 53-
years old, was at age 7 referred to the NIH Clinical Center
because of goiter and hyperthyroidism. The evaluation
showed increased thyroid hormone and TSH levels, with a
net prevalence of hyperthyroid signs, including tachycar-
dia, increased basal metabolic rate, and brisk reflexes.
Further studies demonstrated the absence of a pituitary
adenoma and the rise in TSH following the injection of
TRH. The clinical picture was interpreted as “Thyrotro-
pin-induced hyperthyroidism caused by a selective pitui-
tary resistance to thyroid hormone” [6]. The patient was
initially treated with methimazole, but the therapy was
discontinued because of urticaria, and a sub-total thyroi-
dectomy was performed. The symptoms recurred after
surgery and she was treated with propylthiouracil and, at
age 32, with radioactive iodine ablation. Since then, the
patient has been maintained on levothyroxine and beta-
blockers with the therapeutic goal of clinical euthyroidism
and a TSH level in the high-normal range. The patient
is doing well and has a 20-year old non-affected daughter
in good health. Her therapy consists of levothyroxine
175 mcg daily (3.8 mcg/Kg), Atenolol 25 mg daily; her
most recent laboratory data are: fT4 3.8 ng/dL (0.8-1.5),
TSH 5.05 mcIU/mL (0.4-4.0), cholesterol 199 mg/dL
(<200), triglycerides 81 mg/dL (<150), HDL 60 mg dL
(>60), LDL 123 mg/dL (<100), SHBG 60 nmol/l (18-114),
ACE 41 U/L (16-52). A DEXA scan showed a T-score
of -0.6.
Assignment of ICR haplotype in the index case of PRTH
The index case of PRTH, affected by a previously charac-
terized mutation in the exon 9 (R338W)[13], carried the
heterozygous genotypes C/A in rs17194828, C/T in
rs2596623, and T/C in rs2596622. In order to deduce the
patient’s haplotype, the ICR and the TR b exon 9 of her
unaffected daughter were genotyped. Direct sequencing
showed that the daughter is homozygous for the wild type
R338 allele, heterozygous for the rs17194828 SNP (C/A
genotype), and homozygous for the rs2596623 and
rs2596622 SNPs (C/C and T/T genotypes, respectively).
The data thus indicate that the patient’s mutant W338
allele is in cis with the rs2596623T allele and rs2596622 C
allele, and the unaffected daughter inherited the maternal
haplotype rs2596623C-rs2596622T, and R338 (Figure 2).
D u et ot h eu n a v a i l a b i l i t yo fp a t e r n a lD N A ,w ec a n n o t
assign the genotype for the rs17194828 SNP. Direct
sequencing of a cohort of 45 genomic samples of RTH
NIH cohort patients (Table 1) [8] revealed the presence of
two additional SNPs, the previously described rs6798561G/
A, and a novel one, rs77624520G/C present in a single
case. A schematic representation of the ICR SNPs distribu-
tion in the THRB gene is reported in figure 1. Nο statistical
difference was found between GRTH and PRTH in the
prevalence of each of the SNPs (Table 2).
Transcriptional enhancer function of the human ICR
Analyses of a luciferase reporter construct containing the
human TR b2 promoter demonstrated that in pituitary-
derived GH3 cells, the human ICR stimulated a 10-fold
increase in luciferase expression compared to a reporter
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reporter, the murine ICR also stimulated the human pro-
moter indicating that ICR function was conserved
between species, consistent with the high sequence con-
servation. Compared to the human ICR, the murine ICR
stimulated a greater degree of enhancement of luciferase
activity (p < 0.0001) under the assay conditions used
(Figure 1C). Similarly to previous observations with mur-
ine sequences, no enhancer activity was observed in kid-
ney-derived HEK-293T cells, demonstrating that the
activity of the human ICR is cell type-specific.
Enhancer function of ICR with different SNPs
To evaluate the effects of ICR SNPs on TR b2p r o m o t e r
activity, we generated luciferase reporter constructs con-
taining the SNPs observed in the NIH RTH cohort. We
also generated a rs2596623T-rs2596622C construct repli-
cating the ICR haplotype of the PRTH index case. Com-
pared to the ancestral allele the rs2596623T produced a
significant 30% increase in luciferase expression (p <
0.0001), suggesting that the rs2596623T increased tran-
scriptional activity of the TR b2 promoter. Compared to
rs2596623T alone, the rs2596623T-rs2596622C haplotype
resulted in a marginal, non-significant increase in tran-
scriptional activity (p = 0.543), indicating that the increase
in transcriptional activity is solely due to the rs2596623T
(Figure 3). The other SNPs did not significantly change
expression levels of luciferase.
Discussion
Since the original description of RTH [1], and the subse-
quent description of the PRTH form [6], many investiga-
tors have attempted to demonstrate a correlation
between genotype and phenotype. Although some muta-
tions in the THRB gene may associate preferentially with
PRTH, and among them R338W appears particularly fre-
quent, patients sharing the same mutation can present
the entire range of symptoms associated with the various
forms of RTH [5,13]. Furthermore, although the clinical
Figure 2 Haplotype assignment of the index case of PRTH.
Direct sequencing the ICR and exon 9 of the THRB demonstrated
that the patient carried the heterozygous genotypes C/A in
rs17194828, C/T in rs2596623, and T/C in rs2596622, and the R338W
mutation. Conversely, the unaffected daughter carries the
heterozygous genotype C/A in rs17194828. The data thus indicate
that the patient’s mutant W338 allele is in cis with the rs2596623
T and rs2596622 C allele and the unaffected daughter inherited the
maternal haplotype rs2596623C-rs2596622T, and R338.
Table 1 Clinical presentation and mutations in the exons
9 and 10 of the THRB gene in the NIH RTH cohort
Exon Amino acid change Form n. subjects
9 A317T GRTH 3
9 R320L GRTH 1
9 D322H GRTH 3
9 G332R GRTH 1
9 R338W GRTH 2
PRTH 2
9 G345S GRTH 3
9 G347A GRTH 3
PRTH 1
10 R383H GRTH 1
10 R438H GRTH 1
10 M442V GRTH 1
PRTH 1
10 M442R GRTH 2
PRTH 1
10 FRSH 448 PRTH 1
10 P453H GRTH 7
PRTH 2
Not found n/a GRTH 6
PRTH 3
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is no absolute concordance, and even among siblings the
phenotype differences can be remarkable [14]. In vitro
experiments demonstrated that the R338W mutant
receptor has reduced affinity for TH and a dominant
negative activity typical of RTH syndrome [13,15]. Some
in vitro data suggest that R338W selectively impairs TR
b2 rather than TR b1 isoform function [16], but this find-
ing does not explain completely the clinical presentation
since R338W is also associated with GRTH. Machado
and co-workers reported that a naturally occurring muta-
tion (R429Q) associated with PRTH produces a mutant
TR b product that is specifically defective as a transcrip-
tional repressor, while retaining relatively normal activa-
tor function [17]. This particular mutation is thus in
keeping with a selective PRTH, since a main action of
thyroid hormone in the thyrotroph is the inhibition of
TSH b-subunit gene transcription. Taken together, these
clinical and laboratory observations suggest that various
factors, regardless of the particular THRB mutation, con-
tribute to the clinical presentation of RTH.
Our hypothesis that ICR mutations play a role in the
RTH presentation was further supported by the growing
recognition that sequence variations in cis-acting control
regions determine differences in gene expression levels.
Furthermore, association studies have identified non-cod-
ing sequences as a risk factor for various diseases [18,19].
We have shown that the human ICR, like the murine
ICR, stimulates TR b2 promoter activity in pituitary- but
not in kidney-derived cell lines. The somewhat weaker
activity of the human ICR than the murine ICR may
reflect bias in the assay which was performed in rodent
GH3 cells. Alternatively, there may be real species differ-
ences in the magnitude of the response since thyroid
homeostasis parameters differ in degree between rodents
and humans, as indicated for example by their different
serum ratios of T3/T4 [20], or by different patterns of
expression of deiodinase type-2 [21].
Our study of the NIH RTH cohort demonstrated four
known SNPs and one novel SNP in the human ICR. The
data indicate that in the index case of PRTH a specific
ICR haplotype resides in cis to the R338W THRB gene
Table 2 Prevalence of the SNPs in the intron control region of the THRB gene in the NIH RTH cohort
SNP ID Generalized RTH Pituitary RTH Odds ratio [CI] p value
Subjects Sex Subjects Sex
n = 34 16 M n = 11 8 M
18 F 3 F
rs6798561 n% n %
Genotype
GG 33 97.0 11 100
GA 1 3 0 0 n.a n.a
AA 0 0 0 0
rs17194828 n% n % C C vs. CA plus AA
Genotype
CC 28 82.3 7 63.6
CA 6 17.6 4 36.4 2.7 [0.6 to 12.1] 0.228
AA 0 0 0 0
rs2596623 n% n % C C vs. CT plus TT
Genotype
CC 13 38.2 3 27.3
CT 18 52.9 7 63.6 1.7 [0.4 to 7.4] 0.720
TT 3 8.82 1 9.1
rs2596622 n% n % T T vs. TC plus CC
Genotype
TT 15 44.1 3 27.3
TC 16 47.0 8 72.7 2.1 [0.5 to 9.3] 0.482
CC 3 8.8 0 0
rs77624520 n% n %
Genotype
GG 33 97.0 11 100
GC 1 3 0 0 n.a n.a
CC 0 0 0 0
The SNPs are listed according to the location on the chromosome as reported on Ensembl database.
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of each individual SNP, only rs2596623T gave a signifi-
cant increase in reporter gene expression. rs2596623
resides near the 5’ boundary of a highly conserved 380 bp
sequence in the ICR that is sufficient to direct TR b2 pro-
moter activation in the pituitary but not retina in vivo in
transgenic mice [10]. We speculate that rs2596623T
enhances the recruitment or binding stability of a tran-
scription factor complex that activates the TR b2 promo-
ter in the pituitary.
Our finding tend to support the hypothesis that
rs2596623T stimulates pituitary over-expression of the
pathogenic R338W TR b2 protein, tilting the balance of
expression between the wild type and R338W mutant
THRB alleles in a tissue-specific fashion. This dominant
negative condition would result in a relatively increased
resistance in the pituitary as compared to the peripheral
tissues, recapitulating the patient’s phenotype. Indeed, of
the four unrelated RTH patients who carry the R338W
mutation in the NIH RTH cohort (Table 1), the PRTH
phenotype is limited to the two cases heterozygous for
rs2596623 (C/T). For the second heterozygous case, due
to lack of genetic material from relatives, we are unable
to indicate whether rs2596623T resides in cis with the
pathogenic R338W mutation. Nonetheless one could
speculate that in the two R338W GRTH cases the homo-
zygosity at rs2596623 (C/C or T/T) results in “balanced”
expression of the wild type and mutant receptors in the
pituitary, not dissimilar from peripheral tissues.
No statistical association was found between any SNP
and the phenotypes. This is not surprising because of
the relatively small number of subjects and the lack of
genetic material that would allow us to determine hap-
lotypes in most cases.
Gene expression levels are heritable and several
human diseases have been associated with changes in
enhancer sequences rather than coding exons. For
example, a polymorphic intron sequence that increases
COL1A1 transcription has been associated with changes
in bone mineral density and increased incidence of
osteoporotic bone fractures [22]. Another mutation that
decreases activity of an intronic enhancer in the RET
gene and has been associated with some cases of
Hirschsprung disease [23]. The case of PRTH we
describe is unique in suggesting a genetic “double hit”
that combines an enhancer SNP and a coding exon
change on a single THRB allele.
Conclusions
The molecular characterization of the index case of
PRTH is unique in illustrating a genetic “double hit”
that combines an enhancer SNP and a coding exon
mutation on a single THRB allele resulting in the modu-
lation of the clinical presentation.
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TR b2 promoter-luciferase-ICR reporter construct. The SNPs
detected in the index case of PRTH were introduced in the reporter
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